Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.23M | -3.85M | -3.96M | -3.99M | -4.39M |
| Total Depreciation and Amortization | 120.80K | 120.00K | 119.20K | 118.70K | 118.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.35M | 1.35M | 1.37M | 222.30K | 187.20K |
| Change in Net Operating Assets | 874.30K | 429.50K | 209.20K | -50.00K | -65.50K |
| Cash from Operations | -1.89M | -1.94M | -2.26M | -3.70M | -4.15M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | -1.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 841.00K | 1.13M | 3.28M |
| Cash from Investing | -- | -- | 841.00K | 1.13M | 3.28M |
| Total Debt Issued | 1.43M | 1.50M | 1.50M | 1.50M | 200.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 0.00 | -50.00K | -50.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.43M | 1.50M | 1.50M | 1.45M | 150.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -465.30K | -444.70K | 80.10K | -1.12M | -723.60K |